Israel's national trade union is holding a nationwide strike to protest generic drugmaker Teva's decision to lay off a quarter of its workforce » Read More
By: Tae Kim
Goldman Sachs raises its rating to buy for the generic drugmaker, citing Teva's aggressive cost-cutting targets for the next two years. » Read More
By: Dan Mangan
Jurors were sent home for the day after an investor in Shkreli's company was asked about interactions he had with federal officials. » Read More
Teva Pharmaceutical plans to reduce its workforce by 25 percent and suspend its dividend in a much-anticipated overhaul to help pay back its massive debt.
Some of the most inspiring health success stories of 2017 were the ones most overlooked, says Sue Desmond-Hellmann.
Eli Lilly forecast 2018 earnings and revenue largely above estimates in part due to strong demand for diabetes drug Trulicity and psoriasis drug Taltz.
stocks, market, Jim Cramer, investing, TopGolf, Acadia Pharmaceuticals
Jim Cramer dove into one “wild trader” in the biotech space and why he thinks it’s worth speculating on in a pullback.
CNBC's Meg Tirrell speaks with Hans Bishop, Juno Therapeutics CEO, to discuss the company's down day and progress on its cancer treatment.
Carter Worth, Cornerstone Macro, discusses one lagging stock that could make a comeback.
CNBC's Meg Tirrell speaks with Agios CEO David Schenkein about how the company is zeroing in on cancerous and noncancerous blood diseases.
Spark Therapeutics CEO Jeff Marrazzo speaks to CNBC's Meg Tirrell about the biotech company's hemophilia treatments and the potential for gene therapies.
Celgene and Bluebird Bio find results in treating patients with multiple myeloma.
CNBC's Meg Tirrell speaks with John Cox, Bioverativ CEO, about his company's efforts on one-time gene therapy and the impact tax reform might have on the biotech industry.
CEO Nick Leschly said Bluebird is cautious about calling its drugs cures, though it's "definitely a potential."
The Food and Drug Administration has issued just three warning letters over drug ads in 2017, down from 11 in 2016.
CNBC's Meg Tirrell speaks with Troy Cox, Foundation Medicine CEO, discusses how his company is advancing cancer treatment.
CNBC’s Meg Tirrell speaks with Bluebird Bio CEO Nick Leschly for an exclusive conversation about the future of cancer treatment, drug pricing, and President Trump’s tax plan.
CNBC's Meg Tirrell reports on the biotech and pharma headlines out of the ASH Hematology Conference.
Get the best of CNBC in your inbox